Objectives: To determine the mechanism(s) of macrolide resistance in Haemophilus influenzae isolated from cystic fibrosis (CF) patients participating in a randomized placebo-controlled trial of azithromycin.
Introduction
Untypeable Haemophilus influenzae is a common cause of community-acquired respiratory tract infections in adults and may cause acute sinusitis and/or acute otitis media. 1 H. influenzae is found in the lungs of cystic fibrosis (CF) patients and a 2009 study reported that between 1995 and 2005 the prevalence of H. influenzae increased in these patients. 2 In recent years, macrolides have been used for the treatment of a variety of untypeable H. influenzae infections. 1, 3 Antibiotics have also become important in the treatment of CF patients and randomized placebo-controlled trials of azithromycin in CF patients chronically infected with Pseudomonas aeruginosa have shown an improvement in lung function. 4 The use of long-term azithromycin maintenance therapy in CF populations has been associated with increased macrolide resistance in CF Staphylococcus aureus and H. influenzae isolates as well as Streptococcus pneumoniae and viridans streptococci. 3, 5, 6 Macrolide resistance in S. aureus, S. pneumoniae and Streptococcus spp. has been attributed to the acquisition of known macrolide resistance genes, such as the msr(A) and erm(B) genes. 5, 6 One study found that macrolide-resistant H. influenzae, from patients with community-acquired pneumonia, were macrolide resistant due to mutations in their ribosomal protein genes L4 and L22 and rarely in the 23S rRNA genes, but did not carry acquired macrolide resistance genes. 6 High-level macrolideresistant H. influenzae could be selected in vivo under antibiotic pressure and the resulting isolates had mutations in these ribosomal genes. 7 However, more recently the erm(B) and mef(A) genes were identified in four H. influenzae isolates from CF patients. These isolates had no mutations in the ribosomal L4 or L22 genes or the 23S rRNA gene. The results suggested that acquired macrolide resistance genes found in other Grampositive bacteria from CF patients could be another route for H. influenzae to become macrolide resistant. 8 In the current study, 106 untypeable H. influenzae isolates from children with CF, between 6 and 18 years of age, enrolled in a double-blind, randomized, placebo-control treatment study of azithromycin were characterized for the presence of mutations in the ribosomal protein L4 and L22 genes and for carriage of commonly acquired macrolide resistance genes. One hundred and five of the H. influenzae isolates were either resistant or intermediately resistant to macrolides. All the H. influenzae isolates carried one or more acquired macrolide resistance gene(s) regardless of their phenotypic expression of azithromycin and/or erythromycin resistance. None of the selected isolates carried mutations in either their L4 or their L22 gene. Twenty-five H. influenzae were able to transfer these macrolide resistance genes to both H. influenzae and Gram-positive Enterococcus faecalis recipients, generating macrolide-resistant transconjugants as found in other studies with Gram-negative donors.
9,10

Methods
Study design and bacterial isolates
The source of the H. influenzae isolates was a multicentre, multinational (USA and Canada), double-blind, randomized, placebo-control treatment study of children between 6 and 18 years of age with a diagnosis of CF. The study had human subject approval at each site. One hundred and thirty-one of the participants received azithromycin 250 or 500 mg three times each week, depending on the patients' weight, and 129 participants were given placebo tablets three times each week. H. influenzae was isolated from the patients' sputum at Seattle Children's Hospital microbiology laboratory and forwarded to the University of Washington for further characterization. Isolates were obtained between February 2007 and June 2008. No demographic information was linked to the isolates so it is unknown how many of the isolates came from participants in the treatment and placebo groups. We also do not know if we received multiple isolates from any one participant. A total of 106 H. influenzae isolates were characterized in the current study.
Media
The H. influenzae isolates were grown on chocolate agar with brain heart infusion agar (BHI; Difco, Division of Becton Dickinson & Co., Sparks, MD) supplemented with 5% lysed sheep blood, or brain heart infusion agar supplemented with 10 mg/L haemin, 10 mg/L L-histidine and 2 mg/L nicotinamide adenine dinucleotide and incubated at 36.58C in 5% CO 2 , as previously described.
11 E. faecalis JH2-2 was grown on BHI agar (Difco).
Macrolide resistance
H. influenzae ATCC 49247 (MIC range 0.008-0.03 mg/L) was used as the control strain. 12 The erythromycin and azithromycin MICs for H. influenzae and H. influenzae transconjugants were determined by Etest. Breakpoints of azithromycin MIC of .4 mg/L and erythromycin MIC of .8 mg/L (macrolide resistant), azithromycin 0.5-4 mg/L and erythromycin 1 -8 mg/L (macrolide intermediate) and azithromycin ,0.2 mg/L and erythromycin ,1 mg/L (macrolide susceptible) were used in accordance with current BSAC guidelines. 13 The E. faecalis JH2-2 transconjugants' erythromycin MICs were determined by agar dilution using E. faecalis JH2-2 as a susceptible control. 12 
Detection of antibiotic resistance genes
Previously described PCR assays were used to detect the presence of the macrolide resistance genes erm(B), erm(F), msr(A) and mef(A) in all 106 isolates. 14 -16 Selected isolates were tested for the presence of erm(A) and erm(C) using PCR assays previously described. 14 The PCR products were verified using hybridization with an internal 32 P-labelled probe as described previously. 14, 15 Positive controls for the PCR assays were plasmids with cloned erm and msr(A) genes and E. faecalis JH2-2 was used as a negative control for all the PCR assays.
14
L4 and L22 PCR assays
Selected isolates were used as templates for L4 and L22 PCR assays using PCR conditions of 1 cycle at 948C for 5 min, 948C for 30 s, 538C for 30 s, 728C for 45 s for 35 cycles, and 1 cycle at 728C for 7 min and primers. The resulting PCR products were sequenced and compared with those from H. influenzae Rd as previously described. 6 
Conjugal gene transfer
The mobilities of the erm and mef(A) genes were examined using H. influenzae Rd (azithromycin MIC 1 mg/L, erythromycin MIC 2 mg/L) and/or E. faecalis JH2-2 (erythromycin MIC 2 mg/L) as the recipients as previously described.
9,10,14,17 Twenty-five randomly selected donors that differed in their phenotypic resistance to azithromycin and erythromycin and the type and number of acquired macrolide resistance genes carried were used. Matings were performed at H. influenzae donor:recipient ratios of 1:1 and/or 1:10, while H. influenzae donor to E. faecalis recipient ratios of 25:1 and/or 50:1 were used. Transconjugants obtained from the H. influenzae-H. influenzae matings were selected on chocolate agar supplemented with erythromycin (5 mg/L) and streptomycin (250 mg/L) or rifampicin (10 mg/L). The transconjugants from the H. influenzae-E. faecalis matings were selected on BHI supplemented with erythromycin (10 mg/L) and nalidixic acid (25 mg/L) as previously described. 9, 14, 17 The acquired macrolide gene(s) were confirmed by PCR assay and hybridization with an internal 32 P-labelled probe as previously described. 14 (Table 1) . It was previously found that 26 of 31 H. influenzae strains, with increased macrolide MICs, from community-acquired respiratory tract infections, had mutations in the ribosomal protein L4 and/or L22 genes and 3 isolates had no mutations. 6 Therefore, 25 of the 27 Azi r Erm r and 22 of the 78 Azi i Erm i isolates were tested for mutations in the L4 and L22 genes using the PCR assays developed by Peric et al. 6 None of these isolates had mutations in either L4 or L22 sequences when compared with H. influenzae Rd ( Table 1) .
Presence of acquired macrolide resistance
We had previously shown that Azi r Erm r H. influenzae four domain V 23S rRNA or ribosomal protein L4 and L22 genes. 8 Therefore it was of interest to determine whether the 106 CF isolates in the current study carried either of these genes. The erm(F) gene was included because it has previously been identified in other Gram-negative bacteria and is a commonly found erm gene. 18 H. influenzae, were negative for the three genes.
The erm(C) and erm(A) genes are the third and fourth most commonly found macrolide resistance genes and thus it was of interest to determine whether the seven negative isolates carried either of these two genes. 18 These, along with 10 randomly selected isolates that carried the erm(B), erm(F) and/or mef(A) genes, were tested for carriage of the erm(A) and erm(C) genes. Two isolates carried erm(A), five isolates carried erm(C), one isolate carried both erm(C) and mef(A) and the remaining isolates did not carry erm(A) and/or erm(C) ( Table 1 ). Thus, all 106 H. influenzae isolates were positive for one or more of the macrolide resistance genes examined ( 
Macrolide gene transfer
The erm(A), erm(B), erm(C), erm(F) and mef(A) genes are normally associated with mobile elements. 18 Therefore it was of interest to determine whether selected H. influenzae isolates would be able to transfer their macrolide resistance genes to recipients and if the resulting transconjugants would be macrolide resistant. We chose to use H. influenzae Rd and E. faecalis JH2-2 as recipients. E. faecalis JH2-2 has been used as a recipient in a number of conjugation studies previously since these genes are known to be expressed in the strain. 9 Table 2) . Twelve of the donors carried two macrolide resistance genes and 11 (92%) of the donors transferred both macrolide resistance genes to the transconjugants ( Table 2) . The H. influenzae transconjugants had 4-to 48-fold increased MICs of azithromycin and 4-to 24-fold higher MICs of erythromycin compared with the recipient (Table 2 ). All the H. influenzae transconjugants were resistant to erythromycin and resistant or intermediate to azithromycin. All E. faecalis transconjugants were erythromycin (Table 2) .
Discussion
CF is a genetic disease that is characterized by recurrent pulmonary infections that may damage the lungs. In addition, CF patients are often colonized with a variety of bacteria, including H. influenzae. 2 Since the 1980s the beneficial effect of long-term low-dose treatment with macrolides has been reported, and this treatment has led to improvements in pulmonary functions. 4,5,19 -22 In the current study, 25.5% of the H. influenzae were Azi r Erm r and 73.6% were Azi i Erm i , while 100% carried one or more macrolide resistance gene(s). The Azi r Erm r isolates were identified throughout the 16 months of collection but it is unknown how many of the isolates were from the children in the azithromycin treatment group.
There are a number of possible reasons why the CF H. influenzae in the current study carried macrolide resistance genes while the earlier study did not find acquired macrolide resistance genes. 7 In the previous study the H. influenzae were isolated from an adult population while the current study looked at CF children, of whom half were on azithromycin therapy. These two populations have different microbiota and it is likely that all the CF children in the study had previously had macrolide therapy, since this did not disqualify them from participating in the trial. In addition, macrolide resistant H. influenzae isolation has increased in recent years both in community-acquired infections and from CF patients. This increase might also explain the differences between the H. influenzae from the 1999 -2004 study and the current study. 3 This is the first description of the erm(A), erm(C) and erm(F) genes in H. influenzae and the first description of these genes in bacteria isolated from CF patients, though all of these macrolide resistance genes have previously been identified in oral Gram-negative bacteria. 3, 23 This is the second characterization of erm(B) and mef(A) genes in H. influenzae from CF patients, while the erm(B) and mef(A) genes have both been identified in S. pneumoniae and Streptococcus spp., and erm(B) and msr(A) have been identified in S. aureus from CF patients. 5, 6, 8 It is possible that the current study underestimated the carriage level of both the erm(A) and the erm(C) gene since only 15 of the 106 isolates were screened. Similarly, the number of isolates that carried two or three macrolide resistance genes was probably underestimated. However, as in previous studies of oral Gram-negative bacteria, the mef(A) gene was the most commonly carried macrolide resistance gene in H. influenzae. 23 Previous studies have not found a good correlation between the number of macrolide resistance genes carried and macrolide susceptibilities, while in the current study 56% of the Azi r Erm r isolates carried two or three macrolide resistance genes compared with 26% of the Azi i Erm i isolates, 6 suggesting that there may be some correlation between phenotypic expression of Since all of these macrolide resistance genes have been identified in oral bacteria and in P. aeruginosa from healthy children, it is tempting to speculate that these same genes could be transferred in vivo between bacteria within the lungs or oral cavity of CF patients and H. influenzae could act as a donor or recipient in gene exchange. Further work is needed to determine whether bacteria from CF patients are able to exchange these macrolide resistance genes in vivo and whether current azithromycin therapies increase gene exchange in vivo. Additional work is needed to determine whether continued azithromycin therapy in CF patients routinely increases carriage of macrolide-resistant bacteria and whether this will ultimately reduce the effectiveness of continued or repeated macrolide therapy.
